Table 1 Baseline demographics and disease characteristics of patients in the SPECTRUM Week 8 analysis of the treatment-naïve and previously treated nAMD cohorts.

	Treatment-naïve nAMD (N = 114)	Previously treated nAMD (N = 104)
Age, years	80.8 ± 7.1	79.5 ± 7.3
Female, n (%)	69 (60.5)	60 (57.7)
Race, n (%)^a
Asian	8 (7.0)	0
White	75 (65.8)	90 (86.5)
Not reported	31 (27.2)	14 (13.5)
MNV type, n (%)
Type 1	34 (29.8)	29 (27.9)
Type 2	19 (16.7)	11 (10.6)
Mixed^b	0	0
Type 3	6 (5.3)	5 (4.8)
Missing/unknown/not applicable	55 (48.2)	59 (56.7)
Visual acuity, ETDRS letters^c	60.1 ± 17.4	61.6 ± 19.4
Central retinal thickness, µm^d	358 ± 110	316 ± 102
Median time (range) since nAMD diagnosis, months	0.2 (0.0, 21.9)	36.9 (1.4, 178.9)
Prior treatment for nAMD, n (%)
Aflibercept 2 mg	–	56 (53.9)
Faricimab 6 mg	–	18 (17.3)
Ranibizumab 0.5 mg	–	15 (14.4)
Bevacizumab (variable)	–	4 (3.9)
Brolucizumab 6 mg	–	3 (2.9)
Other	–	1 (1.0)
Steroid	–	0
Missing	–	7 (6.7)

FAS. Data are mean ± SD unless otherwise stated; percentages may not add up to 100 due to rounding. ETDRS Early Treatment of Diabetic Retinopathy Study, FAS full analysis set (all patients receiving ≥1 dose of study drug plus ≥1 post-baseline assessment), MNV macular neovascularisation, nAMD neovascular age-related macular degeneration.
^aData on race were collected in Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates and the United Kingdom only; for France, Denmark, Finland, Netherlands, Norway and Sweden, data on race were not collected according to local law/regulations.
^bCombination of MNV Type 1 and Type 2.
^cVisual outcomes were assessed during routine clinical practice and reported in ETDRS letter scores; where ETDRS charts were unavailable, approximate Snellen scores were converted to ETDRS letter scores.
^dCentral retinal thickness was determined based on physician discretion using optical coherence tomography with the instrument available at each study site.

Search